MACK
Income statement / Annual
Last year (2023), Merrimack Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Merrimack Pharmaceuticals, Inc.'s net income was -$1.18 M.
See Merrimack Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$144.27 M |
$89.26 M |
$102.76 M |
| Cost of Revenue |
$0.00
|
$445.00 K
|
$0.00
|
$0.00
|
$2.23 M
|
$0.00
|
$0.00
|
$6.91 M
|
$46.00 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$445.00 K
|
$0.00
|
$0.00
|
-$2.23 M
|
$0.00
|
$0.00
|
$137.36 M
|
$89.21 M
|
$102.76 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.95
|
1
|
1
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.10 M
|
$49.97 M
|
$67.31 M
|
$160.92 M
|
$160.99 M
|
$138.50 M
|
| General & Administrative Expenses |
$2.18 M
|
$2.17 M
|
$2.62 M
|
$5.01 M
|
$16.17 M
|
$15.60 M
|
$28.45 M
|
$0.00
|
$0.00
|
$30.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.18 M
|
$2.17 M
|
$2.62 M
|
$5.01 M
|
$16.17 M
|
$15.60 M
|
$28.45 M
|
$80.73 M
|
$57.60 M
|
$30.52 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.18 M
|
$2.17 M
|
$2.62 M
|
$5.01 M
|
$27.27 M
|
$65.58 M
|
$95.77 M
|
$241.65 M
|
$218.58 M
|
$169.01 M
|
| Cost And Expenses |
$2.18 M
|
$2.17 M
|
$2.62 M
|
$5.01 M
|
$27.27 M
|
$65.58 M
|
$95.77 M
|
$248.56 M
|
$218.63 M
|
$169.01 M
|
| Interest Income |
$868.00 K
|
$188.00 K
|
$20.00 K
|
$50.00 K
|
$777.00 K
|
$1.30 M
|
$895.00 K
|
$276.00 K
|
$99.00 K
|
$114.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.53 M
|
$956.00 K
|
$34.65 M
|
$43.65 M
|
$19.23 M
|
$18.23 M
|
| Depreciation & Amortization |
$167.90 K
|
-$890.00 K
|
-$288.00 K
|
-$2.28 M
|
-$1.54 M
|
$4.07 M
|
$5.22 M
|
$6.25 M
|
$4.29 M
|
$3.22 M
|
| EBITDA |
$1.01 M |
-$2.62 M |
-$2.76 M |
-$5.15 M |
-$20.26 M |
-$65.58 M |
-$91.08 M |
-$110.14 M |
-$125.28 M |
-$66.26 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.76
|
-1.4
|
-0.64
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.76
|
-1.45
|
-0.64
|
| Total Other Income/Expenses Net |
$1.01 M
|
$633.00 K
|
$164.00 K
|
$2.00 M
|
-$381.00 K
|
-$2.89 M
|
-$22.64 M
|
-$43.38 M
|
-$18.22 M
|
-$17.30 M
|
| Income Before Tax |
-$1.17 M
|
-$1.54 M
|
-$2.45 M
|
-$3.01 M
|
-$22.74 M
|
-$68.46 M
|
-$118.40 M
|
-$153.52 M
|
-$147.79 M
|
-$83.56 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.06
|
-1.66
|
-0.81
|
| Income Tax Expense |
$12.00 K
|
$3.00 K
|
$3.00 K
|
$14.00 K
|
-$1.47 M
|
-$7.70 M
|
-$42.40 M
|
-$13.22 M
|
-$3.92 M
|
-$3.49 M
|
| Net Income |
-$1.18 M
|
-$1.54 M
|
-$2.46 M
|
-$3.03 M
|
-$21.27 M
|
-$40.51 M
|
$472.03 M
|
-$151.74 M
|
-$147.96 M
|
-$83.29 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.05
|
-1.66
|
-0.81
|
| EPS |
-0.0826 |
-0.11 |
-0.18 |
-0.23 |
-1.59 |
-3.04 |
35.67 |
-12.11 |
-13.29 |
-7.98 |
| EPS Diluted |
-0.0826 |
-0.11 |
-0.18 |
-0.23 |
-1.59 |
-3.04 |
35.67 |
-12.11 |
-13.29 |
-7.98 |
| Weighted Average Shares Out |
$14.30 M
|
$13.52 M
|
$13.41 M
|
$13.38 M
|
$13.35 M
|
$13.34 M
|
$13.23 M
|
$12.53 M
|
$11.14 M
|
$10.44 M
|
| Weighted Average Shares Out Diluted |
$14.30 M
|
$13.52 M
|
$13.41 M
|
$13.38 M
|
$13.35 M
|
$13.34 M
|
$13.23 M
|
$12.53 M
|
$11.14 M
|
$10.44 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
